Abeona Therapeutics (NASDAQ:ABEO) CEO Vishwas Seshadri Sells 24,428 Shares

Posted by George Bondi on Jun 9th, 2026

Abeona Therapeutics Inc. (NASDAQ:ABEO – Get Free Report) CEO Vishwas Seshadri sold 24,428 shares of the stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $5.43, for a total value of $132,644.04. Following the completion of the transaction, the chief executive officer owned 1,405,995 shares of the company’s stock, valued at $7,634,552.85. The trade was a 1.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Vishwas Seshadri also recently made the following trade(s):

On Tuesday, June 9th, Vishwas Seshadri sold 31,916 shares of Abeona Therapeutics stock. The stock was sold at an average price of $5.30, for a total value of $169,154.80.

Abeona Therapeutics Trading Up 1.3%

Shares of Abeona Therapeutics stock traded up $0.07 during trading hours on Tuesday, hitting $5.45. The company’s stock had a trading volume of 1,159,558 shares, compared to its average volume of 981,006. The firm has a fifty day moving average of $5.37 and a 200-day moving average of $5.16. The company has a debt-to-equity ratio of 0.03, a quick ratio of 5.70 and a current ratio of 5.89. The stock has a market cap of $310.60 million, a price-to-earnings ratio of 5.62 and a beta of 1.35. Abeona Therapeutics Inc. has a twelve month low of $4.00 and a twelve month high of $7.54.

Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last posted its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.03. The company had revenue of $8.72 million during the quarter, compared to analyst estimates of $4.57 million. Research analysts forecast that Abeona Therapeutics Inc. will post -0.79 EPS for the current year.

Analyst Ratings Changes

ABEO has been the subject of several research reports. Stifel Nicolaus set a $17.00 target price on shares of Abeona Therapeutics in a report on Tuesday, March 17th. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Abeona Therapeutics in a research report on Thursday, May 28th. Wall Street Zen upgraded Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, June 1st. Finally, Oppenheimer reissued an “outperform” rating on shares of Abeona Therapeutics in a research note on Monday, March 9th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $19.00.

Get Our Latest Stock Report on ABEO

Institutional Investors Weigh In On Abeona Therapeutics

Several large investors have recently added to or reduced their stakes in ABEO. Aberdeen Group plc acquired a new stake in Abeona Therapeutics during the 4th quarter worth approximately $3,248,000. AIGH Capital Management LLC acquired a new position in shares of Abeona Therapeutics in the fourth quarter worth $10,540,000. Nan Fung Trinity HK Ltd. grew its stake in shares of Abeona Therapeutics by 70.6% in the fourth quarter. Nan Fung Trinity HK Ltd. now owns 956,770 shares of the biopharmaceutical company’s stock worth $5,042,000 after acquiring an additional 396,000 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Abeona Therapeutics by 38.6% during the first quarter. Renaissance Technologies LLC now owns 161,082 shares of the biopharmaceutical company’s stock worth $722,000 after acquiring an additional 44,882 shares during the period. Finally, Sei Investments Co. increased its position in shares of Abeona Therapeutics by 142.4% during the first quarter. Sei Investments Co. now owns 172,460 shares of the biopharmaceutical company’s stock worth $773,000 after acquiring an additional 101,307 shares during the period. 80.56% of the stock is owned by hedge funds and other institutional investors.

Abeona Therapeutics Company Profile

(Get Free Report)

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.